GlassScriptPhysician profile
Kaynessa Celena Providence
NPI 1013303650
$2,227.11
in general payments reported to CMS, 2019-2025
19 companies · $99.98 in 2025
The $99.98 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2023: $672 · 2024: $1,322 · 2025: $99.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $486.66 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $373.12 | 2022-2025 | |
| Glaxosmithkline, LLC. | $249.33 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $225.13 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $200.32 | 2024-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $90.50 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $83.91 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $82.55 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $66.96 | 2023-2024 | Gemtesa |
| Dexcom, INC. | $65.87 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $62.12 | 2024 | Veozah |
| Pfizer INC. | $62.01 | 2023 | |
| Nevro Corp. | $40.18 | 2024 | Senza |
| Abbott Laboratories | $38.57 | 2023-2024 | Freestyle Libre 2, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.67 | 2024 | Ofev |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.10 | 2023 | Spravato |
| Medtronic, INC. | $19.75 | 2024 | Venaseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.38 | 2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $13.98 | 2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaynessa Providence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.